Merck earnings top estimates amid solid demand for Keytruda cancer drug
Go back to Merck earnings top estimates amid solid demand for Keytruda cancer drug| Merck & Co. (NYSE: MRK) | Delayed: 130.42 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.42 | 52 Week High | $65.46 | |||
| Open | $130.42 | 52 Week Low | $47.97 | |||
| Day High | $130.42 | P/E | 88.72 | |||
| Day Low | $130.42 | EPS | $1.47 | |||
| Volume | 4,091 | |||||

